In the most recent 13F filings, several major institutional investors adjusted their stakes in AbbVie. Commerzbank Aktiengesellschaft FI reduced its holding by 30.5%, selling 39,586 shares and retaining 90,102 shares valued at approximately $20.9 million. Meanwhile, Norges Bank initiated a new position valued at about $4.29 billion, and Vanguard Group added 3.38 million shares, increasing its stake to 177.3 million shares worth roughly $32.9 billion. DZ BANK AG more than doubled its position, acquiring 2.97 million additional shares, and Raymond James Financial lifted its holding by 41.8%, adding 2.75 million shares. Overall, institutional investors and hedge funds now own just over 70% of the company’s shares, underscoring continued confidence among large holders despite recent reallocations.

AbbVie’s fiscal Q3 results exceeded expectations, delivering earnings per share of $1.86 versus consensus of $1.77 and revenue of $15.78 billion compared to forecasts of $15.58 billion. The top‐line increased 9.1% year-over-year, driven by strength across the immunology and oncology franchises. Return on equity stood at an extraordinary 3,216%, while net margin was 4.0%. Management reiterated Q4 EPS guidance in a range of $3.32 to $3.36 and confirmed full‐year consensus EPS of approximately $12.31. The company’s price-to-earnings ratio remains elevated at 166, with a PEG ratio of 0.90, reflecting market expectations for continued growth in specialty medicines.

AbbVie announced a quarterly dividend of $1.73 per share, payable in mid-February to shareholders of record as of January 16. The annualized payout of $6.92 represents a 5.5% increase over the prior quarterly distribution and yields about 3.2% based on current share counts. The dividend payout ratio stands at an aggressive 524%, driven by strong free cash flow generation from key brands. This marks the 55th consecutive annual increase since the company’s spin-off, highlighting AbbVie’s commitment to returning capital to investors alongside reinvestment in its pipeline.